TY - JOUR
T1 - Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract
T2 - World Journal of Urology
AU - Nazzani, S
AU - Preisser, F
AU - Mazzone, E
AU - Tian, Z
AU - Mistretta, FA
AU - Shariat, SF
AU - Soulières, D
AU - Saad, F
AU - Montanari, E
AU - Luzzago, S
AU - Briganti, A
AU - Carmignani, L
AU - Karakiewicz, PI
PY - 2019
Y1 - 2019
N2 - Objectives: To analyze the potential survival benefit of perioperative chemotherapy (CHT) in patients treated with nephroureterectomy (NU) for non-metastatic locally advanced upper tract urothelial carcinoma. Methods: Within the Surveillance, Epidemiology, and End Results database (2004–2014), we identified 1286 patients with T3 or T4, N 0–3 M0 UTUC. Kaplan–Meier plots, as well as multivariable Cox regression models (MCRMs) relying on inverse probability after treatment weighting (IPTW) and landmark analyses, were used to test the effect of CHT vs no CHT on overall mortality (OM) in the overall population (n =1286), as well as after stratification according to lymph node invasion (LNI). Results: Overall, 37.4% patients received CHT. The CHT rate was higher with LNI (62.2% vs 35.2%, p
AB - Objectives: To analyze the potential survival benefit of perioperative chemotherapy (CHT) in patients treated with nephroureterectomy (NU) for non-metastatic locally advanced upper tract urothelial carcinoma. Methods: Within the Surveillance, Epidemiology, and End Results database (2004–2014), we identified 1286 patients with T3 or T4, N 0–3 M0 UTUC. Kaplan–Meier plots, as well as multivariable Cox regression models (MCRMs) relying on inverse probability after treatment weighting (IPTW) and landmark analyses, were used to test the effect of CHT vs no CHT on overall mortality (OM) in the overall population (n =1286), as well as after stratification according to lymph node invasion (LNI). Results: Overall, 37.4% patients received CHT. The CHT rate was higher with LNI (62.2% vs 35.2%, p
U2 - 10.1007/s00345-018-2516-z
DO - 10.1007/s00345-018-2516-z
M3 - Article
VL - 37
SP - 1329
EP - 1337
JO - World J. Urol.
JF - World J. Urol.
SN - 0724-4983
IS - 7
ER -